Caladrius Biosciences Announces Participation in Upcoming Conferences in January 2022
January 04 2022 - 4:05PM
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the
“Company”), a clinical-stage biopharmaceutical company
dedicated to the development of innovative therapies designed to
treat or reverse disease, today announced its participation in
several industry and investor events. All presentations are
pre-recorded and available on-demand through the online conference
platforms.
- Biotech Showcase (January 10–12, 2022 and January
17–19, 2022)Location:
VirtualPresenter: David J. Mazzo, PhD, President
and CEOThe Biotech Showcase will feature insights from top
investors and biopharma executives. For more information on the
conference and how to register, please visit
https://informaconnect.com/biotech-showcase/.
- H.C. Wainwright BioConnect Conference (January 10-13,
2022)Location:
VirtualPresenter: David J. Mazzo, PhD, President
and CEOFor more information on the conference and how to register,
please contact your H.C. Wainwright representative directly or
visit https://hcwevents.com/bioconnect/.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical-stage
biopharmaceutical company dedicated to the development of
innovative therapies designed to treat or reverse disease. We are
developing first-in-class cell therapy products based on the finely
tuned mechanisms for self-repair that exist in the human body. Our
technology leverages and enables these mechanisms in the form of
specific cells, using formulations and modes of delivery unique to
each medical indication.
The Company’s current product candidates include:
XOWNA® (CLBS16), the subject of both a recently completed positive
Phase 2a study and a newly initiated Phase 2b study
(www.freedom-trial.com) in the U.S. for the treatment of coronary
microvascular dysfunction (“CMD”); CLBS12 (HONEDRA® in Japan),
recipient of orphan designation for Buerger’s Disease in the
U.S. and, in Japan, recipient of a SAKIGAKE designation and
eligible for early conditional approval for the treatment of CLI
and Buerger’s Disease based on the results of an ongoing clinical
trial; and CLBS201, designed to assess the safety and efficacy of
CD34+ cell therapy as a treatment for DKD. For more
information on the Company, please
visit www.caladrius.com.
Contact:
Investors:Caladrius Biosciences, Inc.John
MendittoVice President, Investor Relations and Corporate
CommunicationsPhone: 908-842-0084Email:
jmenditto@caladrius.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Apr 2023 to Apr 2024